The future of cell therapy for myocardial regeneration.
There are a number of promising cell therapy products under development for the treatment of heart failure, whether due to myocardial infarction or cardiomyopathy. Looking forward beyond current products in development, there are a multitude of possibilities that hold significant promise; however, cell-based therapies present challenges that are unique to this platform. Results from transplant studies can often be misleading and need to be interpreted in the context of fundamental biologic properties of cells and development. Provided here is a summary of the current and future developments in the field of cell therapy for cardiac regeneration along with some critical insights to interpret the multitude of studies recently undertaken. Summarized are both clinical and preclinical studies that should serve as a useful entrée into this exciting new field of therapeutic development.
Dib
Nabil
N
Arizona Heart Institute, Phoenix, AZ 85006, USA. ndib@azheart.com
Dinsmore
Jonathan
J
D000818:Animals; D009202:Cardiomyopathies / Q000150:complications / Q000628:therapy*; D017690:Cell Transplantation / Q000145:classification / Q000639:trends*; D003131:Combined Modality Therapy / Q000639:trends; D015316:Genetic Therapy / Q000639:trends; D006333:Heart Failure / Q000209:etiology / Q000628:therapy; D006353:Heart-Assist Devices / Q000639:trends; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications / Q000628:therapy*; D014481:United States
D036341:Intercellular Signaling Peptides and Proteins